Martin-Broto J, Cruz J, Penel N, et al. - By performing this single-arm, phase 2 trial, researchers assessed the activity of pazopanib in two distinct cohorts of solitary fibrous tumour: the malignant-dedifferentiated cohort, which was earlier published, and the typical cohort, which is presented here. This inquiry was performed at 11 tertiary hospitals in Italy, France, and Spain, and included adult patients (aged ≥ 18 years) having confirmed metastatic or unresectable typical solitary fibrous tumour of any location, with progression in the previous 6 months (by Choi criteria or Response Evaluation Criteria in Solid Tumors) and had an Eastern Cooperative Oncology Group performance status of 0–2. The participants were administered pazopanib 800 mg once daily, via the oral route, until progression, unacceptable toxicity, withdrawal of consent, non-compliance, or a delay in pazopanib administration of longer than 3 weeks. A median follow-up of 18 months (IQR 14–34) revealed a partial response in 18 (58%) of 31 patients, stable disease in 12 (39%), and one (3%) patient displayed progressive disease as per Choi criteria and central review. Employing Choi criteria, the proportion of overall response was estimated to be 58% (95% CI 34–69). This work represents the first prospective trial of pazopanib for advanced typical solitary fibrous tumour. Pazopanib displayed manageable toxicity and activity in this cohort and thus could be regarded as first-line therapy for advanced typical solitary fibrous tumour.